AviadoBio Ltd.
Astellas Expands Gene Therapy Portfolio with $2.2 Billion Deal for AviadoBio’s Frontotemporal Dementia Treatment
Astellas Pharma Inc., AviadoBio Ltd., Gene Therapy, Frontotemporal Dementia, FTD-GRN, AVB-101, Progranulin Mutations, Neurodegenerative Diseases